bepirovirsen
Coverage of bepirovirsen in the Nexus archive.
- Experimental hepatitis B drug may offer ‘functional cure’ for some patients
An experimental hepatitis B drug called bepirovirsen may offer a 'functional cure' for some patients, with 20% of trial participants maintaining undetectable virus levels after stopping treatment. Developed by GSK and Ionis Pharmaceuticals, the drug is under fast-track FDA review and shows potential to address chronic hepatitis B, which affects over 250 million people globally.
- STAT+: Experimental hepatitis B treatment was a ‘functional cure’ for nearly 1 in 5, new data show
An experimental hepatitis B treatment, GSK’s bepirovirsen, achieved functional cures in 20% and 19% of patients in Phase 3 trials, significantly outperforming current treatments that achieve 1-3% success rates. The drug showed no functional cures in placebo groups, offering hope for a more effective solution to a disease affecting 250-300 million people globally.